Subgroup analysis by prior treatment and disease burden in MONARCH 1: a phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy

Authors
Category Primary study
ConferenceCancer research
Year 2017
This article has no abstract
Epistemonikos ID: 76d338fb1afa7143cf1ac643689bf21fdef5844a
First added on: Feb 08, 2025